CMC Biologics Announce Appointment of David Wolton as VP Manufacturing

14-Oct-2009 - Denmark

CMC Biologics A/S announced the appointment of David Wolton, VP Manufacturing. During his 23 year biotech career, David has held positions with Elan, Wyeth and Lonza.

“We are delighted to add David’s tremendous experience to CMC Biologics. He has a proven track record in managing successful manufacturing teams and will bring new opportunities for production efficiencies”, said Peter Vilby, Chief Operating Officer.

“CMC Biologics continues to attract the highest calibre people in our industry, and David Wolton’s appointment will ensure continued delivery of products to our customers, in the highly demanding regulatory environment of biologicals”, said Mads Laustsen, CEO of CMC Biologics.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Revotar announces promising results suggesting COPD as a potential target for selectin antagonist treatment in humans

GPC Biotech AG Named in Purported Class Action Lawsuit in the United States

Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board

Currently positioned only 5th, China is the fastest growing biotech market in the world

BGU researchers make scientific breakthrough in the fight against neurodegenerative diseases - BGN Technologies secures funding of over $1m. to develop patented treatment

Pivotal phase IIIa trials for Organon's novel oral contraceptive, NOMAC/E2, complete recruitment

Gene Logic Expands GeneExpress Product Line, Launches GeneExpress Women's Health DataSuite - New Product Enables Analysis of Distinctions in Female and Male/ Female Gene Expression

Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years

MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial

Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine - IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer

New findings about stem cells in the brain of patients with epilepsy

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur